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Background: The dynamic nature of device therapies, such as left ventricular assist devices (LVADs) as destination therapy (DT) in end-stage heart 
failure patients, complicates the ability of policymakers to obtain rigorous and timely evidence to guide decisions on their adoption and use. This study 
seeks to address the fundamental challenge posed by the absence of recent RCT data to estimate the incremental cost-effectiveness ratio (ICER) of 
LVADs as DT compared to medical management (MM), by (1) calculating the unpublished ICER during the REMATCH (REM) trial (1998-01) and (2) 
estimating the ICER during more recent eras, including the Post-REMATCH (PREM) (2002-05) and 2nd generation (2G) device eras (2006-08). 
Methods: The REM clinical dataset (N=129) augmented by CMS data and line-item bills was used to calculate the ICER during the study period. 
Charges were converted to costs by using the Ratio-of-Costs-to-Charges for each major resource category. Then a Markov model was developed to 
compare the VAD and MM cohorts during the PREM and 2G eras; input parameters were assigned based on POST-REMATCH registry data (N=205), 
CMS cost data (N=495), and published literature.
Results: During REM, the mean ICER of VAD therapy was $602,361/LY; the major determinants included the index hospitalization cost and 
VAD replacement rates. Significant improvements in the ICER were observed from the 1st ($898,666/LY) to the 2nd half ($505,286/LY) of the 
trial. During the PREM era--assuming no changes in overall survival, improvements in LVAD reliability, and a reduction in the cost of the index 
hospitalization, as well as increased survival and costs in the MM arm with the use of BiVP/ICDs--the modeled ICER improved to $274,100/LY. 
During the 2G era--assuming improvements in survival and improvements in LVAD reliability--the ICER further improved to $122,445/LY.
Conclusions: During REM, the cost effectiveness of LVADs as DT was outside of the accepted range. However, given evolution in LVAD technology 
and its application, the ICER during more recent eras, with concomitant improvements in outcomes and reduction in resource utilization, appears to 
have improved significantly.
